secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2026-01-28T23:59:59+00:00
Accession:  0001628280-26-003717
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira BioSciences appoints Dr. Samit Hirawat (ex-BMS CMO) to its Board of Directors
--------------------------------------------------------------------------------

- Board expanded from 9 to 10 members; Hirawat appointed as Class III director, effective immediately.
- Hirawat brings >25 years industry experience; most recently CMO, EVP, Head of Global Drug Development at Bristol Myers Squibb.
- Hirawat appointed to Science and Technology Committee; receives standard non-employee director compensation.
- Board determined Hirawat is independent under Nasdaq listing standards; no related party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000162828026003717/0001628280-26-003717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000162828026003717/pcrx-20260127.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-003717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer